期刊文献+

(99m)Tc-奥曲肽眼眶显像在甲状腺相关性眼病中的应用 被引量:4

The utility of (99m)Tc-octreotide orbital scintigraphy in thyroid associated ophthalmopathy
原文传递
导出
摘要 目的探讨99mTc-奥曲肽眼眶显像在判断甲状腺相关性眼病(TAO)活动性中的作用。方法 81例TAO患者(151个眼眶)和10例正常对照者(20个眼眶)均行99mTc-奥曲肽眼眶显像,并采用勾画感兴趣区技术计算眼眶与枕部颅骨的奥曲肽摄取比值(O/OCC)。结果 TAO活动组O/OCC比值(1.78±0.44)显著高于TAO非活动组(1.06±0.17)及正常对照组(1.09±0.09),P均<0.001,而TAO非活动组O/OCC比值(1.06±0.17)与正常对照组(1.09±0.09)比较无显著性差异(P>0.05)。所有TAO患者的O/OCC比值与其CAS评分具有很好的相关性(γ=0.899,P<0.001),根据O/OCC比值绘制ROC曲线,曲线下面积为0.979,当O/OCC比值取1.34时,显像敏感性88.3%,特异性94.6%。结论 99mTc-奥曲肽眼眶显像可帮助客观判断TAO的活动性,为临床治疗方案的选择提供依据。 Objective To evaluate the value of 99mTc-octreotide orbital scintigraphy in assessing the activity of thyroid associated ophthalmopathy.Methods 99mTc-octreotide orbital scintigraphy was performed in 81 patients with TAO (151 orbits) and 10 control subjects(20 orbits).The scans were analyzed by a region of interest technique.An uptake ratio between the orbits and the occipital skull (O/OCC) was determined.Results The O/OCC ratio of the active group(1.78±0.44) was higher significantly than that of the inactive group (1.06±0.17) and the control group (1.09±0.09),but no significant difference was found between the inactive group and the control group (P0.05).A statistically significant correlation was found inthe O/OCC ratio versus CAS(γ=0.899,P0.001).The area under the ROC curve for the O/OCC ratio was 0.979,a threshold value of 1.34 for the O/OCC ratio was presented with a sensitivity of 88.3% and a specificity of 94.6%.Conclusion 99mTc-octreotide orbital scintigraphy may be an objective tool in assessing the activity of TAO and may provide a guide to therapeutic strategy.
出处 《北京医学》 CAS 2011年第4期292-294,共3页 Beijing Medical Journal
关键词 甲状腺相关性眼病 99mTc-奥曲肽 放射性核素显像 Thyroid associated ophthalmopathy 99mTc-octreotide Radionuclide imaging
  • 相关文献

参考文献2

二级参考文献23

  • 1段炼,李险峰,陆克义,张承刚,胡光,刘建中,李思进.^(99)Tc^m-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用[J].中华眼科杂志,2006(12):1068-1072. 被引量:18
  • 2崔炯,王中心,杨芳.血清白介素6及其可溶性受体水平与Graves眼病活动性[J].中华内分泌代谢杂志,2004,20(3):244-245. 被引量:4
  • 3朱晓波,庞友鉴,鲍炯琳,李青.甲状腺相关眼病上睑退缩20例的手术治疗[J].国际眼科杂志,2005,5(3):487-489. 被引量:8
  • 4Terwee CB, Dekker FW, Mourits MP, et al.Interpretation and validity of changes in scores on the Graves'ophthalmopathy quality of life questionnaire (QO-QOL)after different treatment.Clin Endo,2002, 54: 391-398.
  • 5Bartalenal L,Pinchera A,Marcocci C.Management of Graves'ophthalmopathy:realityandperspectives.Endocrine Reviews2000,21:168-199.
  • 6Van Dyke HJL.Orbital Graves' disease: a modification of the Nospecs classification.Ophthalmology, 1981,88 : 479.
  • 7Mourits M, Koornneef L,Wiersinga WM., et al.Clinical criteria for the assessment of disease activity in Graves'ophthalmopathy:a novel pproach.Br J Ophthalmol, 1989,73 : 639-644.
  • 8Mourits MP, Prummel MF,Wiersinga WM, et al.Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.Clin Endocrinol( Oxf ), 1997,47 : 9-14.
  • 9BartalenaL,PincheraA,MarcocciC.ManagementofGraves' ophthalmopathy:realityandperspectives.EndocrineReviews,2000,21:168-199.
  • 10Heufelder AE, Somatostatin analogues in GravesJophthalmopathy.Endocrinol Invest, 1997,20(suppl 7) : 50-52.

共引文献3

同被引文献23

  • 1段炼,李险峰,陆克义,张承刚,胡光,刘建中,李思进.^(99)Tc^m-奥曲肽眼眶显像在甲状腺相关眼病中的临床应用[J].中华眼科杂志,2006(12):1068-1072. 被引量:18
  • 2Smith TJ. Pathogenesis of Graves" orbitopathy:a 2010 update. J Endocrinol Invest, 2010, 33: 414-421.
  • 3Salvi M, Vannucchi G, Campi L, et al. Treatment of Graves" dis- ease and associated ophthalmopathy with the auti-CD20 mouoclon- al antibody rituximab: an open study. Eur J Endocrinol, 2007, 156: 33-40.
  • 4Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol, 2008, 158: 273-285.
  • 5Garrity JA, Bahn RS. Pathogenesis of Graves'ophthalmopathy: im- plications for prediction, prevention and treatment. Am J Ophthal- mol, 2006, 142: 147-153.
  • 6Perros P, Krassas GE. Graves orbitopathy: A perspective. Nat Rev Endocrinol, 2009, 5: 312-318.
  • 7Pasquali D, Notaro A, Bonarolorta G, et al. Somatostatin receptor genes are expressed in lymphocytes from retro orbital tissues in Graves' disease. J Clin Endocrinol Metab, 2002, 87: 5125-5129.
  • 8Khanna G, Bushnell D, O'Dorisio MS. Utility of radiolabeled so- matostatin receptor analogues for staging/restaging and treatment of somatostatiu receptor positive pediatric tumors. Oncologist, 2008, 13: 382-389.
  • 9Postema PTE, Krenning EP, Wijingaarde R, et al. l 11-In DT- PA-D-Phel octreotide scintigraphy in thyroidal and orbital Graves' disease: A parameter for disease activity?. J Clin En- docrinol Metab, 1994, 79: 1845-1851.
  • 10Laszlo G, Andras L, Zsolt SF, et al. Imaging of disease activity in Graves'orbitopathy with different methods: comparison of 9'rTC- DTPA and 99fc-depreotide single photon emission tomography, magnetic resonance imaging and clinical activity scores. Nucl Med Commun, 2005, 26: 407-414.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部